Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Stopped Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Mixed-Phenotype Leukemia
- Cancer
- Refractory
- Progression
- Diffuse Large B Cell Lymphoma
- Multiple Myeloma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Myeloma, Plasma-Cell
- Myelomatosis
- Plasma Cell Myeloma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
Sponsor
Biomea Fusion Inc.